NCT01525511View on ClinicalTrials.gov

Pharmacokinetic Study of Primaquine and Dihydroartemisinin-Piperaquine in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
Healthy
Interventions
DRUG

A

"Subject will receive primaquine (PQ) then receive dihydroartemisinin-piperaquine (DHA-PQP)after 1 week washout period and receive PQ together with DHA-PQP for the third regimen after 8 weeks washout period.~Primaquine:~* 1 tablet of primaquine phosphate contains: 26.3 mg (15 mg base)~* Dosage: 2 tablets~DHA-PQP:~* 1 tablet of Eurartesim contains: DHA 40 mg: piperaquine 320 mg~* Dosage: 3 tablets"

DRUG

B

"Subject will receive primaquine (PQ) then receive PQ together dihydroartemisinin-piperaquine (DHA-PQP) after 1 week washout period and receive DHA-PQP for the third regimen after 8 weeks washout period.~Primaquine:~* 1 tablet of primaquine phosphate contains: 26.3 mg (15 mg base)~* Dosage: 2 tablets~DHA-PQP:~* 1 tablet of Eurartesim contains: DHA 40 mg: piperaquine 320 mg~* Dosage: 3 tablets"

Trial Locations (1)

10400

Hospital of Tropical Diseases, Faculty of Tropical Medicine, Mahidol University, Bangkok

All Listed Sponsors
lead

University of Oxford

OTHER

NCT01525511 - Pharmacokinetic Study of Primaquine and Dihydroartemisinin-Piperaquine in Healthy Subjects | Biotech Hunter | Biotech Hunter